EVA Pharma became a licensed manufacturer for the antiviral treatment “Remdesivir – EVA Pharma” under voluntary license, after reaching an agreement with Gilead Sciences Inc.

Remdesivir had been the first medication to be approved by the American Food and Drug Administration for Emergency Use Authorization (EUA) for the treatment of adult and pediatric patients with suspected or laboratory-confirmed SARS-CoV-2 infection and severe COVID-19. After that Remdesivir granted broader authorization by the FDA upon recent clinical studies which show its effect on accelerating COVID-19 patients’ recovery, in mild and moderate conditions not only for severe cases.

Also, it became the first medicine against COVID-19 to be recommended for authorization in the EU by the EMA.

Remdesivir has shown great results according to a clinical trial conducted by the U.S. National Institute of Allergy and Infectious Diseases investigating 1062 hospitalized COVID-19 patients. The study showed the median time to recovery was 10 days for the Remdesivir group compared to 15 days for the placebo group. Other trials have revealed a reduced “mortality rate” to less than 2% when patients are treated with Remdesivir.

EVA Pharma is gladly inviting you to be our partner in the battle against COVID-19, as we are opening doors for exporting Remdesivir-EVA Pharma to 126 countries.
For more info please contact us

Contact US

 


Loading